THE EFFECTS OF DELAYED FUNCTION OF RECIPIENTS OF CADAVER RENAL ALLOGRAFTS
- 31 January 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 41 (2) , 177-181
- https://doi.org/10.1097/00007890-198602000-00009
Abstract
We randomized 158 recipients of cadaver renal allografts to cyclosporine-prednisone (83) or antilymphocyte globulin-azathioprine-prednisone (75) to evaluate: (1) the effects of immunosuppression and pretransplant risk factors on the incidence of delayed graft function, (2) the effects of immunosuppression on the resolution of delayed graft function, and (3) the effects of delayed graft function and pretransplanted risk factors on patient and graft survival. Cyclosporine did not increase the incidence of delayed graft function, compared with ALG-azathioprine-treated patients (33% versus 27%, P = 0.550) but doubled the mean (.+-. SD) duration of oliguria (11.8 .+-. 11.0 versus 5.9 .+-. 3.2 days, P = 0.002) and the number of required dialyses (6.6 .+-. 7.6 versus 3.2 .+-. 1.3, P = 0.031). Retransplanted patients had a higher incidence of delayed graft function that recipients of primary grafts in both the cyclosporine (82% versus 25%, P = 0.001) and ALG-azathioprine (55% versus 22%, P = 0.025) treatment groups. The presence of delayed function reduced one-year graft survival from 89% in all patients without delayed function to 72% (P = 0.011) in all patients with delayed function. Cyclosporine-treated patietns had a slightly, but not significantly better one-year graft survival rate than ALG-azathiprine treated patients both with (73% versus 68%, P = 0.750) and without (92% versus 82%, P = 0.069) delayed graft function. A preservation time longer than 24 hr did not increase the incidence of delayed graft function in cyclosporine-treated patients (34% versus 32%, P = 0.811) or ALG-azathioprine-treated patients (27% versus 27%, P = 0.902). Cyclosporine-treated patients given kidneys with greater than 24 hr of preservation time had reduced graft survival only when delayed graft function occurred (67% versus 92%, P = 0.009). In conclusion, (1) cyclosporine did not increase the incidence of delayed graft function over ALG-azathioprine treatment; (2) cyclosporine did significantly slow recovery of kidneys with delayed function; (3) delayed graft function correlated with poorer graft survival rate in both treatment groups; but (4) prolonged preservation time did not increase the incidence of delayed graft function or reduce graft survival.This publication has 9 references indexed in Scilit:
- THE EFFECT OF CYCLOSPORINE ON EARLY GRAFT FUNCTION IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1983
- Inhibition of T‐Cell Activity by Cyclosporin AScandinavian Journal of Immunology, 1982
- CYCLOSPORIN A AS SOLE IMMUNOSUPPRESSIVE AGENT IN RECIPIENTS OF KIDNEY ALLOGRAFTS FROM CADAVER DONORS - PRELIMINARY-RESULTS OF A EUROPEAN MULTICENTER TRIAL1982
- Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2European Journal of Immunology, 1981
- Cadaver Donor Renal Transplantation by Centers of the Southeastern Organ Procurement FoundationAnnals of Surgery, 1981
- Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process.The Journal of Immunology, 1980
- ACUTE TUBULAR NECROSIS AFTER RENAL TRANSPLANTATIONTransplantation, 1980
- RELATION OF IMMEDIATE POST-TRANSPLANT RENAL FUNCTION TO LONG-TERM FUNCTION IN CADAVER KIDNEY RECIPIENTSTransplantation, 1977
- Biological effects of cyclosporin A: A new antilymphocytic agentInflammation Research, 1976